Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Musculoskeletal | Family Medicine
Multiple Sclerosis Clinical Trials
A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Alabama Neurology Associates
A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis
Birmingham : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Birmingham : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Cullman : North Central Neurology Associates, PC
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Cullman : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
View More »
Cullman : North Central Neurology Associates PC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Cullman : Teva Investigational Site 10329
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Arizona
Phoenix : St. Joseph’s Hospital and Medical Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Gilbert : Synthon investigational site 111
Efficacy and Safety of GTR in Comparison to Copaxone®
Glendale : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Phoenix : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Phoenix : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Phoenix : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Phoenix : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Phoenix : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Phoenix : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Phoenix : St. Joseph's Hospital Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Sun City : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Tempe : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Tucson : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tucson : Northwest NeuroSpecialists, PLLC
A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis
Tucson : Northwest NeuroSpecialists, PLLC
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
Tucson : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tucson : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Tucson : Northwest NeuroSpecialists, LLC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
California
Berkeley : Jordan Research and Education Institute
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Los Angeles : University of Southern California - Keck School of Medicine
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Aliso Viejo : Avanir Pharmaceuticals
PRISM Registry: Pseudobulbar Affect Registry Series
Berkeley : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Berkeley : Alta Bates Summit Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Carmichael : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Downey : Synthon investigational site 139
Efficacy and Safety of GTR in Comparison to Copaxone®
Fresno :
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients
Fresno : Victoria Walton, MD
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Fullerton : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Fullerton : Fullerton Neurology and Headache Center
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Garden Grove : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Irvine : Synthon investigational site 112
Efficacy and Safety of GTR in Comparison to Copaxone®
La Jolla : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
La Jolla : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
La Jolla : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Long Beach : Synthon investigational site 119
Efficacy and Safety of GTR in Comparison to Copaxone®
Long Beach : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Los Angeles : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Los Angeles : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Los Angeles : Keck School of Medicine of the University of Southern Calfornia
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Relapsing Remitting Hispanic Multiple Sclerosis Forms
Los Angeles : USC MS Comprehensive Care Center & Research Group
Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities
Los Angeles : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Los Angeles : USC
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Newport Beach : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Newport Beach : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Newport Beach : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Newport Beach : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Newport Beach : Multiple Sclerosis Center of California & Research
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Oakland : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Oceanside : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Orange : University of California, Irvine
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Pasadena : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sacramento : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sacramento : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Sacramento : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Sacramento : Sutter Institute for Medical Research
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
San Diego : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
San Diego : Coordinated Clinical Research
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
San Francisco : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
San Francisco : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
San Francisco : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
San Francisco : University of California, San Francisco
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
San Francisco : University of California San Francisco
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Stanford : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Temecula : Viking Clinical Research Center
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Torrance : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Valencia : Sanguine Biosciences
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
Colorado
Boulder : Alpine Clinical Research Center
New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS)
Boulder : Alpine Clinical Research Center
New Investigational Medication for Relapsing Remitting Multiple Sclerosis (RRMS) who have had a documented relapse in the last year
Centennial : 1st International Clinical Research Center
Do you have Relapsing Remitting Multiple Sclerosis?
View More »
Aurora : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Aurora : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Aurora : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Aurora : University of Colorado
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Boulder : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Boulder : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Denver : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Denver : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Denver : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Denver : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Englewood : Colorado Neurological Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Fort Collins : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Ft. Collins : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Ft. Collins : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ft. Collins : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Connecticut
New London : Coastal Connecticut Research, LLC
Are You Currently Being Treated for a Relapsing Form of Multiple Sclerosis?
Pawcatuck : CNS Research of CT, Inc.
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
View More »
Derby : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Derby : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Fairfield : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Fairfield : Synthon investigational site 134
Efficacy and Safety of GTR in Comparison to Copaxone®
Hartford : The Mandell Center for Multiple Sclerosis Updated
Assessing Tolerability of Avonex Intramuscular Injections
New Haven : Institute for Neurodegenerative Disorders
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
New London : Synthon investigational site 124
Efficacy and Safety of GTR in Comparison to Copaxone®
Delaware
Newark : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Newark : Christiana Care Health Services
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
District of Columbia
DC : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Washington : Georgetown University Hospital
Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis
Washington : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Washington D.C. : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Florida
Atlantis : Novartis Investigative Site
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Bradenton : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bradenton : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Bradenton : Brandenton Neurology, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Gainesville : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
View More »
Hollywood : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Hollywood : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Hollywood : Sunrise Clinical Research, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Jacksonville : University of Florida
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Maitland : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Maitland : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Maitland : Synthon investigational site 114
Efficacy and Safety of GTR in Comparison to Copaxone®
Maitland : Neurology Associates, PA
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Maitland : Neurology Associates, PA
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Melbourne : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Miami : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Miami : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Miami : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Naples : Collier Neurologic Specialists
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
New Port Richey : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
North Palm Beach : Laszlo J. Mate, MD
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Orlando : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ormond Beach : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Ormond Beach : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Ormond Beach : Neurology Associates of Ormond Beach
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ormond Beach : Neurology Associates of Ormond Beach
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Pompano Beach : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Pompano Beach : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Pompano Beach : Neurological Associates
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Pompano Beach : Neurological Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Port Charlotte : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Port Charlotte : Synthon investigational site 120
Efficacy and Safety of GTR in Comparison to Copaxone®
Port Orange : Progressive Medical Research
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Sarasota : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Sarasota : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sarasota : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Sarasota : Roskamp Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
South Miami : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
St. Petersburg : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
St. Petersburg : Suncoast Neuroscience Associates, Inc.
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
St. Petersburg : Suncoast Neuroscience Associates, Inc
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Sunrise : Synthon investigational site 130
Efficacy and Safety of GTR in Comparison to Copaxone®
Tallahassee : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Tallahassee : AMO Corporation
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Tampa : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tampa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tampa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tampa : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Tampa : Synthon investigational site 115
Efficacy and Safety of GTR in Comparison to Copaxone®
Tampa : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Tampa : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Tampa : Novartis Investigative Site
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Tampa : University of South Florida
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Tampa : Axiom Clinical Research of Florida
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Vero Beach : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Vero Beach : Geodyssey Research, LLC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Vero Beach : MS Center of Vero Beach
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Vero Beach : Vero Beach Neurology
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
West Palm Beach : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Weston : Cleveland Clinic Florida
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Georgia
Atlanta : NeuroTrials Research
Living with Multiple Sclerosis? Enrolling for a 96-week, non-placebo, comparative trial.
Atlanta : Neurotrials Research, Inc.
Multiple Sclerosis
View More »
Atlanta : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Atlanta : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Atlanta : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Atlanta : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Atlanta : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Atlanta : Shepard Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Atlanta : Shepherd Center
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Decatur : Neurostudies
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Hawaii
Honolulu : Leo Maher, MD
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Illinois
Elk Grove Village : Alexian Brothers Hospital Network
A 6 month, randomized, active comparator, open-label, multi-center study to evaluate patient outcomes, safety and tolerability of Fingolimod (FTY720) 0.5mg/day in patients with relapsing remitting MS who are candidates for MS therapy change from previous disease modifying therapy (EPOC).
Flossmoor : South Suburban Neurology
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Barrington : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Champaign : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Chicago : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Chicago : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Chicago : Rush-Presbyterian St. Luke's Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Chicago : University of Chicago
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
Elk Grove Village : Synthon investigational site 107
Efficacy and Safety of GTR in Comparison to Copaxone®
Evanston : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Flossmoor : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Flossmoor : South Suburban Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Lake Barrington : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Lake Barrington : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Lake Barrington : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Lille Cedex : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Northbrook : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Northbrook : Synthon investigational site 132
Efficacy and Safety of GTR in Comparison to Copaxone®
Northbrook : Consultants in Neurology
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Peoria : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Peoria : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Indiana
Avon : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ft. Wayne : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Indianapolis : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Indianapolis : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Indianapolis : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
View More »
Indianapolis : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Indianapolis : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Indianapolis : Josephson Wallack Munshower Neurology, P.C.
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Indianapolis : Josephson Wallack Munshower Neurology, PC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Merrillville : Neuroscience Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Wayne : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Iowa
Des Moines : Mercy Ruan Neurology Clinic Res Ct.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Kansas
Lenexa : MidAmerica Neuroscience Research Foundation DBA: Rowe Neurology Institute
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Kansas City : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Kansas City : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kansas City : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kansas City : Synthon investigational site 118
Efficacy and Safety of GTR in Comparison to Copaxone®
Kansas City : University of Kansas Medical Center
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Lenexa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lenexa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lenexa : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Lenexa : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Lenexa : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Lenexa : MidAmerica Neuroscience Institute
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Lenexa : Mid America Neuroscience Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Overland Park : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Topeka : Precise Clinical Research
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Topeka : Cotton O'Neil Clinical Research Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Kentucky
Lexington : Associates in Neurology, P.S.C.
A Phase 3 study of PEGylated Interferon Beta-1a vs Placebo for subjects with Relapsing Remitting Multiple Sclerosis.
Lexington : Associates in Neurology, P.S.C.
A Phase 3 Study to determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex (Interferon-beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis.
Lexington : Associates in Neurology, P.S.C.
A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to evaluate the efficacy and safety of Ocrelizumab in comparison to Interferon Beta-1a (Rebif) in patients with Relapsing Multiple Sclerosis.
Lexington : Associates in Neurology, P.S.C.
Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10mg twice daily) in Patients with Multiple Sclerosis. Sponsored by: Acorda Therapeutics.
Lexington : University of Kentucky Chandler Medical Center
Help us to make progress in Secondary Progressive MS
Lexington : Associates in Neurology, P.S.C.
Multicenter, open-labeled, randomized, active comparator research study to evaluate patient outcome, safety and tolerability of an investigational medicine in patients with Relapsing forms of Multiple Sclerosis and who are candidates for MS therapy change from previous disease modifying therapy.
Lexington : Associates in Neurology, P.S.C.
This trial is evaluating the safety and efficacy of an investigational oral medication for the treatment of spasticity in patients with multiple sclerosis (MS).
View More »
Lexington : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Lexington : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lexington : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Lexington : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Lexington : Associates in Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Lexington : Associates in Neurology
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Louisville : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Louisville : Synthon investigational site 140
Efficacy and Safety of GTR in Comparison to Copaxone®
Louisville : University of Louisville (recruiting nationwide)
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
Louisville : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Louisville : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Louisville : Norton Healthcare, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Louisiana
Shreveport : Louisiana State University
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Maine
Scarbrough : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Maryland
Baltimore : University of Maryland
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Baltimore : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Baltimore : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Baltimore : Johns Hopkins University School of Medicine
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Baltimore : University of Maryland
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Baltimore : Johns Hopkins University
Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis
Bethesda : Bethesda Neurology, LLC
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Massachusetts
Bellingham : CNS Research of MA, Inc.
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
Boston : Brigham Women’s Hospital
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Brockton : Beacon Clinical Research
Are You Currently Being Treated for a Relapsing Remitting Form of Multiple Sclerosis?
View More »
Boston : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Boston : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Boston : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Boston : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Boston : Beth Israel Deaconess Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Boston : Caritas St. Elizabeth's Hospital
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Brookline : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Burlington : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Cambridge : Novartis Investigative Site
Pregnancy Registry Trial
Cambridge : Outcome Sciences, Inc
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Lexington : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Milford : Milford Regional Medical Center
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Springfield : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Springfield : Springfield Neurology Associates, LLC
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Worcester : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Worcester : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Worcester : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Worcester : Fallon Clinic at Worcester Medical Center
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Michigan
Ann Arbor : Michigan Head-Pain & Neurological Institute Updated
Clinical Trial for the treatment of spasticity in Patients with MS
Ann Arbor : Michigan Head-Pain & Neurological Institute Updated
Clinical Trial for the treatment of spasticity in Patients with MS
Bingham Farms : QUEST Research Institute
Multiple Sclerosis Spasticity Study
View More »
Ann Arbor : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ann Arbor : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Bingham Farms : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Clinton TWP : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Clinton Twp : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Clinton Twp : Michigan Neurology Associates, P.C.
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Detroit : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Detroit : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Detroit : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Detroit : Henry Ford Health System
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Detroit : Wayne State University
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
East Lansing : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Farmington Hills : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Farmington Hills : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Minneapolis : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Novi : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Minnesota
Minneapolis : University of Minnesota
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Edina : Minneapolis Clinic of Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Golden Valley : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Golden Valley : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Golden Valley : Synthon investigational site 103
Efficacy and Safety of GTR in Comparison to Copaxone®
Mississippi
Jackson : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Missouri
Chesterfield : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kansas City : Saint Luke's Hospital
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Springfield : St.John's Research Institute, Inc
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
St. Louis : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
St. Louis : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
St. Louis : Washington University (John L. Trotter MS Center)
Ampyra for Optic Neuritis in MS
St. Louis : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Montana
Great Falls : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Great Falls : Advanced Neurology Specialists
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Great Falls : Benefis Physician Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Nebraska
Lincoln : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Lincoln : Neurology Associates PC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Omaha : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Omaha : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
New Hampshire
Lebanon : Dartmouth Hitchcock Medical Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Lebanon : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
New Jersey
Freehold : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Marlton : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Newark : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Newark : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Newark : UMDNJ
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
View More »
Teaneck : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Teaneck : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Teaneck : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Toms River : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Toms River : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
New Mexico
Albuquerque : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Albuquerque : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
New York
Buffalo : Jacobs Neurological Institute
Buffalo General Hospital
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Mineola : Winthrop University Hospital Clinical Trials Center
Multiple Sclerosis - (MS) Primary Progressive Multiple Sclerosis
New York : Judith Jaffe Multiple Sclerosis Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Albany : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Albany : Albany Medical Center Hospital
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Albany : Neurological Associates of Albany, PC
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Amherst : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Latham : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Latham : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Latham : Empire Neurology, PC
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Latham : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Latham : Empire Neurology, PC
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
New York : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
New York : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
New York : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
New York : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
New York : NYU-Hospital for Joint Diseases
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
New York : Mount Sinai School of Medicine
Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks
Patchogue : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Patchogue : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Patchogue : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Patchogue : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Patchogue : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Patchogue : South Shore Neurologic Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Plainview : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Plainview : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Plainview : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Plainview : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Plainview : Island Neurological Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Plainview : Island Neurological Assoicates, PC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Rochester : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Rochester : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Rochester : University of Rochester
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
Rochester : University of Rochester
Memantine for Spasticity in MS Patients
Rochester : University of Rochester
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Rochester : University of Rochester Medical Center
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Stony Brook : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Stony Brook : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Stony Brook : Stony Brook University
Mindfulness Based Stress Reduction in Multiple Sclerosis (MS)
Stony Brook : SUNY at Stony Brook
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
White Plains : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
North Carolina
Chapel Hill : University of North Carolina
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
Charlotte : PMG Research of Charlotte
Multiple Sclerosis (MS) Research Opportunity
Charlotte : Duke University
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Concord : Duke University
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Winston Salem : PMG Research of Winston-Salem
Have you been diagnosed with a relapsing form of Multiple Sclerosis?
View More »
Advance : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Advance : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Advance : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Asheville : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Asheville : Novartis Investigative Site
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
Chapel Hill : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Charlotte : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Charlotte : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Charlotte : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Charlotte : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Charlotte : Synthon investigational site 125
Efficacy and Safety of GTR in Comparison to Copaxone®
Charlotte :
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients
Charlotte : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Charlotte : The Neurological Institute, PA
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
Charlotte : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Charlotte : Carolinas Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Charlotte : The Neurological Institute, PA
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Hickory : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
High Point : Cornerstone Neurology
NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness
Raleigh : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Raleigh : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Raleigh : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Raleigh : Synthon investigational site 141
Efficacy and Safety of GTR in Comparison to Copaxone®
Raliegh :
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients
Winston-Salem : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Winston-Salem : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
North Dakota
Bismarck : Legacy Pharma Research
MS - Central Neuropathic Pain due to Multiple Sclerosis
Bismarck : Legacy Pharma Research
MS - Central Neuropathic Pain due to Multiple Sclerosis
View More »
Grand Forks : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Ohio
Akron : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Akron : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Akron : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Akron :
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients
Akron : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
View More »
Bellevue : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Cincinnati : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Cleveland : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Cleveland : Synthon investigational site 106
Efficacy and Safety of GTR in Comparison to Copaxone®
Cleveland : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Cleveland : Cleveland Clinic Foundation
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Columbus : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Columbus : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Columbus : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Columbus : Teva Investigational Site 10317
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Dayton : Synthon investigational site 135
Efficacy and Safety of GTR in Comparison to Copaxone®
Dayton : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Dayton : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Dayton : Neurology Specialists, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Dayton : Neurology Specialists, Inc
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Gahanna : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Uniontown : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Uniontown : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Oklahoma
Oklahoma City : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Oklahoma City : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Oklahoma City : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Oklahoma City : Oklahoma Medical Research Foundation
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Oregon
Eugene : Clinical Trials of America, Inc
Male and female aged 18-65 years, have you been diagnosed with multiple sclerosis?
Portland : Providence St. Vincent Medical Center
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Clackamas : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Corvallis : The Corvallis Clinic, P.C.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Medford : Providence Medical Group - Medford
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Portland : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Portland : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Portland : Oregon Health and Science University
Dalfampridine for Imbalance in Multiple Sclerosis
Portland : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Portland : Providence Multiple Sclerosis Center
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Portland : Providence St. Vincent Medical Center - Northwest MS Center
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Pennsylvania
Abington : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Abington : Synthon investigational site 132
Efficacy and Safety of GTR in Comparison to Copaxone®
Abington : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Allentown : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Altoona : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
View More »
Greensburg : Westmoreland Neurology
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Indiana : Synthon investigational site 109
Efficacy and Safety of GTR in Comparison to Copaxone®
Philadelphia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Philadelphia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Philadelphia : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Philadelphia : Drexel University College of Medicine
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Philadelphia : University of Pennsylvania Health System
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Pittsburgh : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Pittsburgh : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
Pittsburgh : Research Protocol Management Solutions
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Wilkes Barre : Geisinger Health System
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Rhode Island
Providence : CNS Research of RI, Inc.
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis.
Providence : The Neurology Foundation, Inc.
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Providence : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
South Carolina
Greenville : Duke University
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
View More »
Greenville : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tennessee
Franklin : Advanced Neurosciences Institute
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Cordova : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Franklin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Franklin : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Franklin : Synthon investigational site 137
Efficacy and Safety of GTR in Comparison to Copaxone®
Franklin : Advanced Neurosciences Institute
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Knoxville : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Knoxville : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Memphis : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Nashville : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nashville : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Nashville : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Texas
Amarillo : Texas Oncology
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
Dallas : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Dallas : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Dallas : Baylor Research Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Dallas : University of Texas Southwestern
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
View More »
Dallas : UT Southwestern
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Houston : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Houston : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Houston : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Houston : Baylor College of Medicine
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Houston : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Lubbock : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Round Rock : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Round Rock : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Round Rock : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Round Rock : Central Texas Neurology Consultants, P.A.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Round Rock : Central Texas Neurology
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
San Antonio : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
San Antonio : Osmotica Study Site Updated
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
San Antonio : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
San Antonio : Innovative Clinical Trials, Bexar Diagnostic Medicine Assoc.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
San Antonio : Integra Clinical Research, LLC
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Sherman : Texoma Neurology Associates
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Terrell : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Utah
Salt Lake City : Rocky Mountain MS Clinic
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
Salt Lake City : Rocky Mountain MS Clinic
Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control
Salt Lake City : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Salt Lake City : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Salt Lake City : Rocky Mountain MS Clinic
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Vermont
Burlington : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Burlington : Fletcher Allen Health Care - Neurology Service
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Virginia
Charlottesville : Charlottesville Medical Research
Are You Currently Being Treated for a Relapsing Remitting Form of Multiple Sclerosis?
Charlottesville : Charlottesville Medical Research
Suffering from Relapsing Remitting Form of Multiple Sclerosis?
View More »
Charlottesville : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Charlottesville : Synthon investigational site 122
Efficacy and Safety of GTR in Comparison to Copaxone®
Henrico : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Henrico : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Henrico : Neurological Associates
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Newport News : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Newport News : Hampton Roads Neurology
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Norfolk : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Roanoke : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Vienna : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Vienna : MS Center of Greater Washington
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Washington
Lynnwood : Clinical Trials of America, Inc
Are you a man or woman over 18, and suffering from spasticity due to multiple sclerosis?
Seattle : Benaroya Research Institute at Virginia Mason
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis (ACCLAIM)
View More »
Issaquah : Swedish Neuroscience Institute
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Kirkland : MS Center at Evergreen
A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis
Kirkland : MS Center at Evergreen Healthcare
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients With Multiple Sclerosis Taking Glatiramer Acetate
Kirkland : MS Center at Evergreen Hospital
Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis
Mountlake Terrace :
Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis
Seattle : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Seattle : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Seattle : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Seattle :
Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients
Seattle : Novartis Investigative Site
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
Seattle : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Seattle : Swedish Medical Center
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Seattle : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Seattle : Swedish Neuroscience Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Seattle : Pacific Medical Centers
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Seattle : Swedish Neuroscience Institute
Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis
Seattle : MS Hub
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
Tacoma : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tacoma : XenoPort Clinical Site
Arbaclofen Placarbil for the Treatment of Spasticity in Subjects With Multiple Sclerosis (MS)
Tacoma : Research Site
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Tacoma : MultiCare Health System
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Tacoma : MultiCare Research Institute
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
West Virginia
Wisconsin
Green Bay : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Milwaukee : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Albania
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Argentina
Buenos Aires : Fundación Argentina Contra las Enfermedades Neurológicas del Envejecimiento - FACENE
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Buenos Aires : Hospital Churruca-Visca
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Capital Federal : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Ciudad Autonoma Bs As : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ciudad Autonoma de Buenos Aires : Instituto de Neurologia Cognitiva
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
View More »
Ciudad Autonoma de Buenos Aires : Hospital Britanico de Buenos Aires
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ciudad Autonoma de Buenos Aires : Medeos - Centro de Medicina Integral e Investigación Clínica
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ciudad Autónoma de Buenos Aires : Hospital Italiano
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ciudad de Buenos Aires : Instituto Argentino de Investigacion Neurologica
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Ciudad de Buenos Airesa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Guaymallen : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Rosario : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Salta : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
San Juan : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
San Miguel de Tucumán : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Australia
Fitzroy : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Hobart : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kanwal : Novartis Investigative Site
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
Austria
Innsbruck : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Linz : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Linz : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Linz : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations :
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
View More »
Salzburg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Vienna : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Vienna : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Wien : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Belarus
Bitebsk : Synthon investigational site 401
Efficacy and Safety of GTR in Comparison to Copaxone®
Gomel : Synthon investigational site 402
Efficacy and Safety of GTR in Comparison to Copaxone®
Grodno : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Grodno : Synthon investigational site 403
Efficacy and Safety of GTR in Comparison to Copaxone®
Minsk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Minsk : Synthon investigational site 404
Efficacy and Safety of GTR in Comparison to Copaxone®
Minsk : Synthon investigational site 407
Efficacy and Safety of GTR in Comparison to Copaxone®
Minsk : Synthon investigational site 408
Efficacy and Safety of GTR in Comparison to Copaxone®
Minsk : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Vitebsk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Vitebsk : Synthon investigational site 405
Efficacy and Safety of GTR in Comparison to Copaxone®
Belgium
Antwerpen : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Ath : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Brabant Wallon : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Brasschaat : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Brugge : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Brussels : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bruxelles : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bruxelles : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Charleroi : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Edegem : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Esneux : Centre Hospitalier Universitaire de Liège Ourthe Ambléve
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Hainaut : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Kortrijk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
La Louviere : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
La Louviere : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Leuven : UZ Gasthuisberg
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Leuven : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Liege : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Liege :
Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis
Liège : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Limburg : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Luxembourg : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Many Locations :
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Melsbroek : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Oost-Vlaanderen : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Overpelt : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Roeselare : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sijsele : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Sijsele-damme : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
West-Vlaanderen : Research Site
Avonex-evaluation of Quality of Life and Convenience in Belgian Patients - The AVAIL Study
Wilrijk : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Bosnia and Herzegovina
Banja Luka : Synthon investigational site 486
Efficacy and Safety of GTR in Comparison to Copaxone®
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Sarajevo : Synthon investigational site 487
Efficacy and Safety of GTR in Comparison to Copaxone®
Sarajewo : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Tuzla : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tuzla : Synthon investigational site 488
Efficacy and Safety of GTR in Comparison to Copaxone®
Brazil
Belo Horizonte : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Belo Horizonte : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Goiania : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Goiânia : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Joinville : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Porto Alegre : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Porto Alegre : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Rio de Janeiro : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Rio de Janeiro : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sao Paulo : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bulgaria
Pleven : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Pleven : Synthon investigational site 207
Efficacy and Safety of GTR in Comparison to Copaxone®
Plovdiv : Synthon investigational site 206
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sofia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Sofia : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sofia : Synthon investigational site 202
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : Synthon investigational site 203
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : Synthon investigational site 205
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : Synthon investigational site 208
Efficacy and Safety of GTR in Comparison to Copaxone®
Sofia : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Varna : Synthon investigational site 201
Efficacy and Safety of GTR in Comparison to Copaxone®
Canada
Bracebridge : South Muskoka Medical Clinic
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Burlington : Central Contact
Canadian Avonex PEN Productivity Study
Calgary : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Calgary : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Calgary : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
Edmonton : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Edmonton : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Edmonton : University of Alberta
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Gatineau : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Gatineau : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Gatineau : Clinique Neuro-Outaouais
Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients
Gatineau : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Greenfield Park : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Greenfield Park : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Greenfield Park : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Greenfield Park : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Halifax : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Halifax : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Halifax : Dalhousie MS Research Unit
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Kingston : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
London : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
London : London Health Sciences Centre
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Montreal : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Montreal : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Montreal : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Montreal : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Montreal : McGill University - MNI
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Montréal : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ottawa : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Ottawa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ottawa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Ottawa : The Ottawa Hospital
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Saint John : Saint John Regional Hospital
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Toronto : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Toronto : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Toronto : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Toronto : Sunnybrook Health Sciences Centre
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Vancouver : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Vancouver : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Vancouver : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Vancouver : Vancouver Coastal Health: University of British Columbia Hospital
Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous Interferon-b1b in Patients With Multiple Sclerosis
Vancouver : MS Clinic UBC Hospital
Pharmacogenomics of Drug Safety in Multiple Sclerosis
Victoria :
Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis
Winnipeg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
China
Many locations :
China Betaferon Adherence, Coping and Nurse Support Study
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Nanjing : Nanjing University Medical College Affiliated Drum Tower Hospital
Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
Colombia
Barranquilla : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Bogotá : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Medellin : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Croatia
Osijek : Synthon investigational site 477
Efficacy and Safety of GTR in Comparison to Copaxone®
Pula : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Varazdin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Zagreb : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Zagreb : Synthon investigational site 475
Efficacy and Safety of GTR in Comparison to Copaxone®
View More »
Zagreb : Synthon investigational site 476
Efficacy and Safety of GTR in Comparison to Copaxone®
Zagreb : Synthon investigational site 478
Efficacy and Safety of GTR in Comparison to Copaxone®
Zagreb : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Czech Republic
Brno : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Brno : Synthon investigational site 217
Efficacy and Safety of GTR in Comparison to Copaxone®
Brno : Synthon investigational site 211
Efficacy and Safety of GTR in Comparison to Copaxone®
Brno : Fakultni nemocnice u sv. Anny v Brne
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Brno : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
View More »
Brno-bohunice : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Hradec Kralove : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Hradec Kralove : Novartis Investigative Site
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
Hradec Kralove : Fakultni nemocnice Hradec Kralove
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Jihlava : Nemocnice Jihlava, prispevkova organizace
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Jihlava : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Katowice : Synthon investigational site 240
Efficacy and Safety of GTR in Comparison to Copaxone®
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Olomouc : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Olomouc : Synthon investigational site 210
Efficacy and Safety of GTR in Comparison to Copaxone®
Olomouc :
Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis
Ostrava : Synthon investigational site 212
Efficacy and Safety of GTR in Comparison to Copaxone®
Ostrava : Fakultni Nemocnice Ostrava
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Pardubice : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Praha : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Praha : Synthon investigational site 215
Efficacy and Safety of GTR in Comparison to Copaxone®
Praha : Synthon investigational site 216
Efficacy and Safety of GTR in Comparison to Copaxone®
Praha : Faculty Hospital Motol
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Praha : THOMAYER Faculty Hospital
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Praha 2 : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Praha 2 : Novartis Investigative Site
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
Praha 2 : Vseobecna fakultni nemocnice v Praze
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Praha 4 - Krc : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Teplice : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Teplice : Synthon investigational site 214
Efficacy and Safety of GTR in Comparison to Copaxone®
Zlin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Denmark
Aarhus C : MS Clinic, Department of Neurology, Aarhus University Hospital
Multiple Sclerosis and Progressive Resistance Training
Aarhus C : Sport Science, Aarhus University
Multiple Sclerosis and Progressive Resistance Training
Arthus C : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Esbjerg : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Esbjerg : Research Site
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis
View More »
Esbjerg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Glostrup : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Glostrup : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
København Ø : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Odense : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Sønderborg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Vejle : Research Site
A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Patients With Multiple Sclerosis
Vejle : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Viborg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Egypt
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Estonia
Kohtla-Jarve : Synthon investigational site 297
Efficacy and Safety of GTR in Comparison to Copaxone®
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Tallinn : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tallinn : Synthon investigational site 296
Efficacy and Safety of GTR in Comparison to Copaxone®
Tallinn : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
View More »
Tallinn : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Tartu : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Finland
Helsinki : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Helsinki : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Helsinki : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Helsinski : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Jyväskylä : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
View More »
Jyväskylä : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations :
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Tampere : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tampere : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tampere : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Tampere : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Turku : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Turku : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Turku : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
France
Amiens cedex : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Angers : Novartis Investigative Site
Fingolimod -Response According to Coping - Evaluation
Bordeaux : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bordeaux : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bordeaux : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
Bordeaux : Service de Neurologie - Pôle des Neurosciences Cliniques, CHU de Bordeaux.
Randomised Controlled Clinical Trial of Cognitive Rehabilitation in Multiple Sclerosis
Bron : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bron cedex : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Caen : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Clermont Ferrand : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Clermont-ferrand : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Creteil : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Dijon : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Garches : Hopital Raymond Poincaré
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Lille : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lille : Hopital HURIET
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Lommé : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lyon : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lyon : Hôpital Lyon Sud -Hospices Civils de Lyon
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Marseille : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Marseille : Hopital de la conception
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Marseille :
Safety and Efficacy Study OnabotulinumtoxinA for the Treatment of Urinary Incontinence in Multiple Sclerosis
Marseille : La Timone University Hospital (APHM)
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Marseille cedex 5 : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Montpellier : CHU Hôpital Gui de Chauliac Service de Neurologie B
A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly
Montpellier : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Montpellier : Novartis Investigative Site
FTY720 in Patients With Primary Progressive Multiple Sclerosis
Montpellier cedex 5 : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nancy : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nancy : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Nancy : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nantes : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nantes : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nantes : CHU Hotel Dieu
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Nice : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nice : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nimes : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Nimes : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Paris : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Paris : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Paris : Groupe Hospitalier La Pitié Salpetriere
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Paris : Hopital Tenon
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Paris : La Pitie-Salpaetriere Hospital (APHP)
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Ploemeur : CMRRF Kerpape
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Poissy : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Poissy : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Reims : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Reims : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Reims : Maison Blanche Hospital
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Rennes : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Rennes : Rennes University Hospital
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Rouen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Rouen : CHU Rouen - Hopital Charles Nicolle
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Strasbourg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Strasbourg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Strasbourg : Nouvel Hopital civil de Strasbourg
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Toulouse : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Toulouse : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Toulouse : CHU Toulouse - Hopital Rangueil
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Toulouse : Purpan Hospital
The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System.
Toulouse cedex 9 : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tourcoing : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Georgia
Tbilisi : Synthon investigational site 529
Efficacy and Safety of GTR in Comparison to Copaxone®
Tbilisi : Synthon investigational site 526
Efficacy and Safety of GTR in Comparison to Copaxone®
Tbilisi : Synthon investigational site 527
Efficacy and Safety of GTR in Comparison to Copaxone®
Tbilisi : Synthon investigational site 528
Efficacy and Safety of GTR in Comparison to Copaxone®
Tbilisi : Synthon investigational site 530
Efficacy and Safety of GTR in Comparison to Copaxone®
View More »
Tbilisi : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Germany
Aachen : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Aachen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Aalen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Abensberg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Achim : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
View More »
Achim : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Achim : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Altenholz-Stift : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Altenholz-Stift : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Alzenau : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Alzenau : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Asbach : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Aschaffenburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Aschaffenburg : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Aschaffenburg : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Aschaffenburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Augsburg : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Augsburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bad Honnef : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Bad Honnef : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bad Krozingen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bad Mergentheim : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bad Mergentheim : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Bad Mergentheim : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bad Neustadt / Saale : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Bad Saarow : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Bad Saarow : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bad Wilbad : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bad Wildbad : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Baesweiler : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Bamberg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bamberg : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Bamberg : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Bamberg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bamberg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Bayreuth : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bayreuth : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bayreuth : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Berg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Berlin : Charité Universitätsmedizin
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Berlin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Berlin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Berlin : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Berlin : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Berlin : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Berlin : Synthon investigational site 221
Efficacy and Safety of GTR in Comparison to Copaxone®
Berlin : St. Hedwig Hospital, Department of Urology
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Berlin : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Berlin : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Berlin : Morphosys Investigative Site
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Berlin : GSK Investigational Site
Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis
Berlin : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Berlin : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Bielefeld : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Bielefeld : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Bielefeld : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Böblingen : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Böblingen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bochum : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bochum : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bochum : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Bochum : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Bochum : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Bochum : Research Site
Fampridine Pregnancy Exposure Registry
Bochum : Novartis Investigative Site
Pregnancy Registry Trial
Bochum : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bogen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bonn : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bonn : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bottrop : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bremen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Bremerhaven : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Bremerhaven : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Buchholz : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Buchholz : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Butzbach : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Butzbach : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Celle : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Chemnitz : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Darmstadt : Please contact the Merck Communications Service for Recruiting locations
A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device
Dillingen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Dortmund : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Dresden : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Dresden : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Dresden : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Dresden : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Dresden : Synthon investigational site 220
Efficacy and Safety of GTR in Comparison to Copaxone®
Dresden : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Dresden : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Duesseldorf : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Duesseldorf : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Düren : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Düsseldorf : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Düsseldorf : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Düsseldorf : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Eltville : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Emden : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Emmendingen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Erbach : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Erbach : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Erfurt : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Erfurt : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Erlangen : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Erlangen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Essen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Essen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Essen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Frankfurt : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Frankfurt : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Frankfurt : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Frankfurt : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Frankfurt : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Freiburg : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Freiburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Freiburg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Fulda : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Gelnhausen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Gelsenkirchen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
GIEßEN : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Gilching : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Göttingen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Grevenbroich : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Grevenbroich : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Grevenbroich : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Gummersbach : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Halle : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Halle (Saale) : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Hamburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Hamburg : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Hamburg : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Hamburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Hamburg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Hannover : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Hannover : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Hannover : Synthon investigational site 224
Efficacy and Safety of GTR in Comparison to Copaxone®
Hannover : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Hannover : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Heidelberg : Novartis Investigative Site
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®
Heidelberg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Heidelberg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Heidelberg : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Heidelberg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Heidenheim : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Heidenheim : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Hennigsdorf : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Herford : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Herford : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Hoppegarten : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Itzehoe : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Jena : Synthon investigational site 227
Efficacy and Safety of GTR in Comparison to Copaxone®
Jena : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Jena : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Juelich : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Kandel : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Kassel : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Kassel : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Kassel : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Kassel : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Kastellaun : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Kastellaun : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Kiel : Universitätsklinik Kiel
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Klingenmünster : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Klingenmünster : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Koeln : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Koeln : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Köln : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Köln : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Köln : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Königsbrück : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Krefeld : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Landshut : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Lappersdorf : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Leipzig : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Leipzig : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Leipzig : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Leipzig : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Leipzig : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Leverkusen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Lohr am Main : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Lohr am Main : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Ludwigshafen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Lüneburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Lutherstadt Eisleben : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Magdeburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Mainz : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Mannheim : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Mannheim : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Many Locations :
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Many Locations :
Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations :
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Marburg : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Marburg : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Merzig : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Mittweida : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Mönchengladbach : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Muenchen : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Muenchen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Muenchen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Muenster : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Muenster : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Muenster : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Mülheim : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
München : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
München : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
München : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
München : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Munich : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Münster : Klinik und Poliklinik für Neurologie
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Münster : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Münster : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Münster : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Münster : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Nagold : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Neuberg : Research Site
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice
Neuburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Neuburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Neunkirchen : Städtisches Klinikum Neunkirchen
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Neuruppin : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Neusäß : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Neu-Ulm : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Nienburg : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Nümbrecht : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Oberhausen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Oldenburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Oldenburg : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Oldenburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Osnabrück : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Osnabrück : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Ostfildern : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Ostfildern : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Paderborn : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Pforzheim : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Potsdam : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Potsdam : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Potsdam : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Prien : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Prien : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Prien : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Quakenbrück : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Regensburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Regensburg : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Regensburg : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Remscheid : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Roesrath : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Rostock : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Rostock : Synthon investigational site 222
Efficacy and Safety of GTR in Comparison to Copaxone®
Rostock : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Rostock : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Rüdersdorf : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Schwalmstadt-Treysa : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Siegen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Siegen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Siegen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Singen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Sinsheim : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Sinsheim : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Sinsheim : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Stade : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Stadtroda : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Stadtroda : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Stuttgart : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Stuttgart : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Stuttgart : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Telgte : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Telgte : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Teupitz : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Teupitz : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Teupitz : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Troisdorf : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Tübingen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tübingen : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Tübingen : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Tübingen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Tuebingen : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
ULM : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
ULM : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Ulm : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Ulm : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Ulm : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Unterhaching : Novartis Investigative Site
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
Unterhaching : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Wasserburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Weil am Rhein : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Wendlingen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Wermsdorf : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Wermsdorf : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Westerstede : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Westerstede : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Wiesbaden : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Wiesbaden : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Wolfratshausen : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Würzburg : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Würzburg : Novartis Investigative Site
STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)
Zwickau : Novartis Investigative Site
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
Greece
Athens : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Thessaloniki : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Hungary
Budapest : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Budapest : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Budapest : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Budapest : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Esztergom : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Esztergom : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Pécs : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Szeged : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Veszprem : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Ireland
Dublin : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Dublin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Israel
Ashkelon : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Haifa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Jerusalem : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
View More »
Petach Tikva : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Ramat Gan : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Ramat-gan : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Safed : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Tel Aviv : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Italy
Acquaviva Delle Fonti : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ancona : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Ancona : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Ancona : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Baggiovara : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
View More »
Bari : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bari : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bari : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Barletta : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Bergamo : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Biella : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Biella : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Bolzano : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Brescia : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Cagliari : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Caltanissetta : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Catania : Synthon investigational site 238
Efficacy and Safety of GTR in Comparison to Copaxone®
Catania : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Catania : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Catanzaro : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Cefalu : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Cefalu : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Cefalu : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Cefalù : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Chieti : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Chieti : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Como : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Coppito : Synthon investigational site 234
Efficacy and Safety of GTR in Comparison to Copaxone®
Cuneo : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Empoli : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Fidenza : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Firenze : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Firenze : Ospedale Careggi
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Florence : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Foggia : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Gallarate : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Gallarate : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Gallarate : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Genova : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Genova : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Genova : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Genova : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Imperia : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
L'Aquila : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Lecce : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Legnago : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Livorno : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Messina : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Messina : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Milan : Institute of Experimental Neurology
Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Milano : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Milano : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Milano : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Milano : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Milano : Synthon investigational site 233
Efficacy and Safety of GTR in Comparison to Copaxone®
Milano : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Milano : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Modena : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Montichiari : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Montichiari : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Monza : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Naples : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Naples : Investigational Site
Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a
Napoli : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Napoli : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Novara : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Orbassano : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Padova : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Palermo : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Palermo : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Pavia : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Pavia : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Perugia : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Pisa : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Pozzilli : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Reggio Calabria : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Roma : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Roma : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Roma : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Roma : Research Site Updated
Dose-finding Study of MT-1303
Roma : Novartis Investigative Site
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
Roma : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Rome : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Rome : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
San Donato Milanese : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Torrette Di Ancona : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Trieste : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Verona : Novartis Investigative Site
Patients With RRMS:Candidates for MS Therapy Change
Japan
Chiba, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Chiba, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Fukuoka, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Fukuoka, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Hiroshima, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
View More »
Hiroshima, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Kawagoe, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kawagoe, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Kodaira, : University of British Columbia
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kodaira, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Kyoto, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kyoto, : London Health Sciences Centre
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Kyoto, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Morioka, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Morioka, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Niigata, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Niigata, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Osaka, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Osaka, : Univ of Calgary / Foothills MC
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Osaka, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Sapporo, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sapporo, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Sendai, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sendai, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Suita, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Suita, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Tokorozawa, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Tokorozawa, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Tokyo, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Tokyo, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Tsukuba, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Tsukuba, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Ube, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Ube, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Yokohama, : Research Site
BG00002 Study in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Yokohama, : Research Site
Extension Study to Evaluate Safety and Efficacy of BG00002 in Japanese Subjects With Relapsing-Remitting Multiple Sclerosis
Jordan
Amman : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Kazakhstan
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Korea, Republic of
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Kuwait
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Latvia
Riga : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Riga : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Riga : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Lebanon
Beirut : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Libyan Arab Jamahiriya
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Lithuania
Kaunas : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kaunas : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kaunas : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Klaipeda : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Klaipeda : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
Klaipeda : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Siauliai : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Vilnius : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Malaysia
Kuala Lumpur : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Penang : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Mexico
Aguascalientes : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Aguascalientes : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Chihuahua : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Chihuahua : Synthon investigational site 518
Efficacy and Safety of GTR in Comparison to Copaxone®
Culiacan : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Guadalajara : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Guadalajara : Synthon investigational site 516
Efficacy and Safety of GTR in Comparison to Copaxone®
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Mexico : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Mexico : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Mexico : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Mexico : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Mexico City : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Mexico City : Synthon investigational site 514
Efficacy and Safety of GTR in Comparison to Copaxone®
Monterrey : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Monterrey : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Monterrey : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Monterrey : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Morelia : Synthon investigational site 515
Efficacy and Safety of GTR in Comparison to Copaxone®
San Luis de Potosi : Synthon investigational site 522
Efficacy and Safety of GTR in Comparison to Copaxone®
San Luis Potosí : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Tijuana : Hospital Angeles
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
Tlalnepantla : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Moldova, Republic of
Chisinau : Synthon investigational site 548
Efficacy and Safety of GTR in Comparison to Copaxone®
Chisinau : Synthon investigational site 549
Efficacy and Safety of GTR in Comparison to Copaxone®
Chisinau : Synthon investigational site 550
Efficacy and Safety of GTR in Comparison to Copaxone®
Chisinau : Synthon investigational site 547
Efficacy and Safety of GTR in Comparison to Copaxone®
Netherlands
Amsterdam : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Amsterdam : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Amsterdam : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Breda : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Breda : Amphia Ziekenhuis
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
View More »
Eindhoven : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Gouda : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Hertogenbosch : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Hoorn : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Leeuwarden : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Nieuwegein : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nieuwegein : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Nieuwegein : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Nijmegen : UMC ST Radboud Nijmegen, Department of Urology
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
Rotterdam : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sittard : Maasland Ziekenhuis
Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)
Sittard : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Sittard-Geleen : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Sittard-geleen : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sittard-Geleen : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
New Zealand
Hamilton : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Hamilton : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Wellington : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Norway
Bergen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bergen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Lørenskog : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Molde : Molde Hospital
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice
View More »
Oslo : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Oslo : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Stavanger : Stavanger University Hospital
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra® When Used In Routine Medical Practice
Tønsberg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Panama
Panama City : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Peru
Bellavista : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Jesus Maria : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
La Perla : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Lima : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
San Isidro : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
View More »
San Isidro : Novartis Investigative Site
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
Poland
Bialystok : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Bialystok : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bialystok : Synthon investigational site 244
Efficacy and Safety of GTR in Comparison to Copaxone®
Bydgoszcz : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Czeladz : Szpital Powiatowy w Czeladzi
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
View More »
Gdansk : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Gdansk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Gdansk : Morphosys Investigative Site
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Jaroslaw : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Jaroslaw : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Katowice : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Katowice : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Katowice : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Katowice : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Katowice : Synthon investigational site 241
Efficacy and Safety of GTR in Comparison to Copaxone®
Katowice : Synthon investigational site 245
Efficacy and Safety of GTR in Comparison to Copaxone®
Katowice : Synthon investigational site 242
Efficacy and Safety of GTR in Comparison to Copaxone®
Katowice : Diagnomed Clinical Research Sp. z.o.o.
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Katowice : Niepubliczny Zaklad Opieki Zdrowotnej NEURO-MEDIC
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Katowice : Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Katowice : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Konskie : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Konskie : Zespol Opieki Zdrowotnej w Konskich
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Krakow : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Krakow : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Krakow : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Lodz : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Lodz : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lodz : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lodz : Synthon investigational site 247
Efficacy and Safety of GTR in Comparison to Copaxone®
Lublin : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Lublin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lublin : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lublin : Synthon investigational site 251
Efficacy and Safety of GTR in Comparison to Copaxone®
Many Locations :
Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)
Olsztyn : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Olsztyn : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Olsztyn : Synthon investigational site 243
Efficacy and Safety of GTR in Comparison to Copaxone®
Plewiska : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Plewiska : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Plewiska : Specjalistyczny Gabinet Neurologiczny
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Poznan : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Poznan : Synthon investigational site 248
Efficacy and Safety of GTR in Comparison to Copaxone®
Poznan : Morphosys Investigative Site
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Poznan : Niepubliczny Zaklad Opieki Zdrowotnej NEURO-KARD Ilkowski i Partnerzy Spolka Partnerska Lekarzy
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Szczecin : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Szczecin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Szczecin : Osrodek Badan Klinicznych Indywidualnej Specjalistycznej Praktyki Lekarskiej
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Szczecin : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Warsaw : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Warszawa : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Warszawa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Warszawa : Synthon investigational site 246
Efficacy and Safety of GTR in Comparison to Copaxone®
Warszawa : NZOZ Centrum Medyczne Mazovia
Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Warszawa-Miedzylesie : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Wroclaw : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Wroclaw : Synthon investigational site 249
Efficacy and Safety of GTR in Comparison to Copaxone®
Portugal
Almada : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Almada : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Amadora : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Braga : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Coimbra : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Coimbra : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lisboa : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lisboa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lisbon : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Porto : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Porto : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Puerto Rico
Guaynabo : Caribbean Center for Clinical Research, Inc.
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
Romania
Bucharest : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Bucharest : Synthon investigational site 260
Efficacy and Safety of GTR in Comparison to Copaxone®
Bucharest : Synthon investigational site 264
Efficacy and Safety of GTR in Comparison to Copaxone®
Bucharest : Synthon investigational site 262
Efficacy and Safety of GTR in Comparison to Copaxone®
Bucharest : Synthon investigational site 263
Efficacy and Safety of GTR in Comparison to Copaxone®
View More »
Campulung : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Cluj-Napoca : Synthon investigational site 266
Efficacy and Safety of GTR in Comparison to Copaxone®
Targu Mures : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Timisoara : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Russian Federation
Arkhangelsk : Synthon investigational site 438
Efficacy and Safety of GTR in Comparison to Copaxone®
Barnaul : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Barnaul : Synthon investigational site 435
Efficacy and Safety of GTR in Comparison to Copaxone®
Barnaul : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Belgorod : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
View More »
Belgorod : Synthon investigational site 437
Efficacy and Safety of GTR in Comparison to Copaxone®
Belgorod : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Ekaterinburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ekaterinburg : Synthon investigational site 431
Efficacy and Safety of GTR in Comparison to Copaxone®
Kaluga : Synthon investigational site 445
Efficacy and Safety of GTR in Comparison to Copaxone®
Kazan : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Kazan : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kazan : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kazan : Synthon investigational site 427
Efficacy and Safety of GTR in Comparison to Copaxone®
Kazan : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Kemerovo : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kemerovo : Synthon investigational site 432
Efficacy and Safety of GTR in Comparison to Copaxone®
Kemerovo : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Khanty-Mantiysk : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Kirov : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kirov : Synthon investigational site 447
Efficacy and Safety of GTR in Comparison to Copaxone®
Kirov : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Krasnodar : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Krasnoyarsk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Kursk : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Lipetsk : Synthon investigational site 446
Efficacy and Safety of GTR in Comparison to Copaxone®
Moscow : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Moscow : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Moscow : Synthon investigational site 571
Efficacy and Safety of GTR in Comparison to Copaxone®
Moscow : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Moscow : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
N.Novgorod : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Nizhniy Novgorod : Synthon investigational site 428
Efficacy and Safety of GTR in Comparison to Copaxone®
Nizhniy Novgorod : Synthon investigational site 429
Efficacy and Safety of GTR in Comparison to Copaxone®
Nizhniy Novgorod : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Nizhny Novgorod : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Nizniy Novgorod : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Novosibirsk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Novosibirsk : Synthon investigational site 434
Efficacy and Safety of GTR in Comparison to Copaxone®
Novosibirsk : Synthon investigational site 442
Efficacy and Safety of GTR in Comparison to Copaxone®
Novosibirsk : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Penza : Synthon investigational site 444
Efficacy and Safety of GTR in Comparison to Copaxone®
Perm : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Perm : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Pyatigorsk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Pyatigorsk : Synthon investigational site 433
Efficacy and Safety of GTR in Comparison to Copaxone®
Samara : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Samara : Synthon investigational site 424
Efficacy and Safety of GTR in Comparison to Copaxone®
Saransk : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Saratov : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Saratov : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Smolensk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Smolensk : Synthon investigational site 420
Efficacy and Safety of GTR in Comparison to Copaxone®
Smolensk : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
St. Petersburg : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
St. Petersburg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
St. Petersburg : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
St.Petersburg : Synthon investigational site 430
Efficacy and Safety of GTR in Comparison to Copaxone®
St.Petersburg : Synthon investigational site 426
Efficacy and Safety of GTR in Comparison to Copaxone®
St.Petersburg : Synthon investigational site 421
Efficacy and Safety of GTR in Comparison to Copaxone®
St.Petersburg : Synthon investigational site 440
Efficacy and Safety of GTR in Comparison to Copaxone®
Tomsk : Synthon investigational site 422
Efficacy and Safety of GTR in Comparison to Copaxone®
Tomsk : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Tumen : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Tver : Synthon investigational site 441
Efficacy and Safety of GTR in Comparison to Copaxone®
Tver : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Tyumen : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Tyumen : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tyumen : Synthon investigational site 425
Efficacy and Safety of GTR in Comparison to Copaxone®
Ufa : Synthon investigational site 423
Efficacy and Safety of GTR in Comparison to Copaxone®
Ufa : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Ulyanovsk : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Volgograd : Synthon investigational site 443
Efficacy and Safety of GTR in Comparison to Copaxone®
Yaroslavl : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Yaroslavl : Novartis Investigative Site
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
Saudi Arabia
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Serbia
Belgrade : Synthon investigational site 451
Efficacy and Safety of GTR in Comparison to Copaxone®
Belgrade : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Kragujevac : Synthon investigational site 453
Efficacy and Safety of GTR in Comparison to Copaxone®
Novi Sad : Synthon investigational site 452
Efficacy and Safety of GTR in Comparison to Copaxone®
Slovakia
Banska Bystrica : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Bratislava : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Levoca : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Martin : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Nitra : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Zilina : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Slovenia
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
South Africa
Cape Town : Synthon investigational site 501
Efficacy and Safety of GTR in Comparison to Copaxone®
Durban : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Durban : Synthon investigational site 505
Efficacy and Safety of GTR in Comparison to Copaxone®
Pretoria : Synthon investigational site 502
Efficacy and Safety of GTR in Comparison to Copaxone®
Spain
Alicante : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Alicante : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Badalona : Hospital Germans Trias i Pujol
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Badalona : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Barcelona : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
View More »
Barcelona : Hospital de la Santa Creu i Sant Pau
A Phase 2b/3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis
Barcelona : Hospital del Mar
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Barcelona : Hospital Clinic i Provincial
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Barcelona : Hospital Vall d'Hebrón
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Barcelona : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Barcelona : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Barcelona : Novartis Investigative Site
Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy
Barcelona : Novartis Investigative Site
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Barcelona : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Barcelona : Hospital del Mar
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Barcelona : Hospital Vall D´Hebron
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Bilbao : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
El Palmar : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
El Palmar : Hospital Universitario Virgen de la Arrixaca
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Girona : Hospital Universitari Josep Trueta
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Girona : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Girona : Research Site
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Subjects With Relapsing MS
Girona : Hospital Universitari de Girona Dr. Josep Trueta
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
L'hospitalet de Llobregat : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Madrid : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Madrid : Hospital Universitario 12 de Octubre
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Hospital Universitario La Princesa
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Hospital Universitario La Paz
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Hospital Universitario Puerta del Hierro
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Hospital Clínico San Carlos
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Madrid : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Madrid : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Madrid : Research Site Updated
Dose-finding Study of MT-1303
Majadahonda : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Malaga : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Malaga : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Malaga : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Málaga : Hospital Regional Universitario Carlos Haya
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
San Sebastian : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Santa Cruz de Tenerife : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Santiago de Compostela : Complexo Hospitalario Universitario de Santiago
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Santiago de Compostela : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sevilla : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Sevilla : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sevilla : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Sevilla : Hospital Universitario Vírgen Macarena
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Valencia : Hospital Universitario La Fe
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Valencia : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Vigo : Hospital Xeral Vigo
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Sweden
Göteborg : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Göteborg : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Göteborg : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Göteborg : Novartis Investigative Site
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Örebro : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
View More »
Stockholm : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Stockholm : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Stockholm : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Stockholm : Novartis Investigative Site
OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Umeå : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Umeå : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Switzerland
Basel : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Basel : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Basel : University Hospital Basel
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Bern : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Geneva : Hopitaux Universitaires de Genève - HUG
Safety Study of GNbAC1 in Multiple Sclerosis Patients
View More »
Lausanne : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Lugano : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Lugano : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lugano : Ospedale Regionale di Lugano - Civico
Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis
Lugano : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
St. Gallen : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Zug : Biogen Idec International GmbH, Global Medical Affairs
TOP: IMA-06-02 Tysabri Observational Program
Zurich : Research Site
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
Syrian Arab Republic
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Taiwan
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Tunisia
Mannouba : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Many Locations :
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
Monastir : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sfax : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Tunis : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Turkey
Ankara : Novartis Investigative Site
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
Ankara : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Inciralti Izmir : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Istanbul : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Izmir : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
View More »
Kocaeli : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Samsun : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Trabzon : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Yenisehir-izmir : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Ukraine
Cherkassy : Synthon investigational site 474
Efficacy and Safety of GTR in Comparison to Copaxone®
Chernihiv : Synthon investigational site 459
Efficacy and Safety of GTR in Comparison to Copaxone®
Chernivtsi : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Chernivtsi : Synthon investigational site 463
Efficacy and Safety of GTR in Comparison to Copaxone®
Dnepropetrovsk : Synthon investigational site 458
Efficacy and Safety of GTR in Comparison to Copaxone®
View More »
Dnepropetrovsk : Synthon investigational site 472
Efficacy and Safety of GTR in Comparison to Copaxone®
Dnipropetrovsk : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Dnipropetrovsk : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Donetsk : Synthon investigational site 468
Efficacy and Safety of GTR in Comparison to Copaxone®
Donetsk : Synthon investigational site 464
Efficacy and Safety of GTR in Comparison to Copaxone®
Ivano-Frankivsk : Synthon investigational site 495
Efficacy and Safety of GTR in Comparison to Copaxone®
Kharkiv : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kharkiv : Synthon investigational site 469
Efficacy and Safety of GTR in Comparison to Copaxone®
Kharkiv : Synthon investigational site 461
Efficacy and Safety of GTR in Comparison to Copaxone®
Kharkov : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kiev : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kiev : XX
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Kyiv : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Kyiv : Synthon investigational site 455
Efficacy and Safety of GTR in Comparison to Copaxone®
Kyiv : Synthon investigational site 496
Efficacy and Safety of GTR in Comparison to Copaxone®
Kyiv : Synthon investigational site 456
Efficacy and Safety of GTR in Comparison to Copaxone®
Lutsk : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lutsk : Synthon investigational site 473
Efficacy and Safety of GTR in Comparison to Copaxone®
Lviv : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Lviv : Synthon investigational site 462
Efficacy and Safety of GTR in Comparison to Copaxone®
Lviv : Synthon investigational site 466
Efficacy and Safety of GTR in Comparison to Copaxone®
Lviv : Synthon investigational site 497
Efficacy and Safety of GTR in Comparison to Copaxone®
Mariupol : Synthon investigational site 498
Efficacy and Safety of GTR in Comparison to Copaxone®
Odesa : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Odessa : Synthon investigational site 457
Efficacy and Safety of GTR in Comparison to Copaxone®
Poltava : Synthon investigational site 470
Efficacy and Safety of GTR in Comparison to Copaxone®
Simferopol : Synthon investigational site 467
Efficacy and Safety of GTR in Comparison to Copaxone®
Uzhhorod : Synthon investigational site 471
Efficacy and Safety of GTR in Comparison to Copaxone®
Vinnytsia : Synthon investigational site 465
Efficacy and Safety of GTR in Comparison to Copaxone®
Vinnytsya : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Zhytomyr : Synthon investigational site 460
Efficacy and Safety of GTR in Comparison to Copaxone®
United Kingdom
Brighton : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Brighton : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Edgbaston : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Edinburgh : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Exeter : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
View More »
Exeter : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Hammersmith : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Irvine : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Liverpool : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Liverpool : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
London : GSK Investigational Site
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
London : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
London : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
London : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
London : Research Site Updated
Dose-finding Study of MT-1303
London : University College of London, Institute of Neurology
Efficacy of Clean Intermittent Catheterization in MS Patients With Bladder Dysfunction
London : Imperial College NHS Trust
Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
London : Research Site
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing-Remitting Multiple Sclerosis
Manchester : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Manchester : Morhosys Investigative Site
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Many Locations :
Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
Merck KGaA Communication Center for recruiting locations : Please conatact the
The Impact of Disease Modifying Therapies (DMTs) and Associated Support Services on Patient Reported Experience Measures (PREMs) and Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Morriston : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Newcastle Upon Tyne : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Newcastle Upon Tyne : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Norwich : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nottingham : GSK Investigational Site
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
Nottingham : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Nottingham : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Nottingham : MorphoSys Investigative Site
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Plymouth : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Plymouth : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Sheffield : Research Site Updated
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS
Sheffield : Synthon investigational site 284
Efficacy and Safety of GTR in Comparison to Copaxone®
Stoke on Trent : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Stoke on Trent : Synthon investigational site 281
Efficacy and Safety of GTR in Comparison to Copaxone®
Swansea : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Swansea : Research Site
Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in Patients With Multiple Sclerosis.
Torquay : Synthon investigational site 283
Efficacy and Safety of GTR in Comparison to Copaxone®
Truro : Updated
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis
Truro : Synthon investigational site 280
Efficacy and Safety of GTR in Comparison to Copaxone®
Uruguay
Indianapolis : Updated
A Study of Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis
Venezuela
Many Locations :
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
